A positive allosteric modulator of the β1AR with antagonist activity for catecholaminergic polymorphic ventricular tachycardia
Authors:
- Alyssa GroganAGAlyssa Grogan
- Robin M. PerelliRPRobin M. Perelli
- Seungkirl AhnSASeungkirl Ahn
- Haoran JiangHJHaoran Jiang
- Arun JyothidasanAJArun Jyothidasan
- Damini SoodDSDamini Sood
- Chongzhao YouCYChongzhao You
- David I. IsraelDIDavid I. Israel
- Alex ShaginianASAlex Shaginian
- Qiuxia ChenQCQiuxia Chen
- Jian LiuJLJian Liu
- Jialu WangJWJialu Wang
Open Access
- 16 October 2025
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (24)
Abstract
Orthosteric beta blockers represent the leading pharmacological intervention for managing heart diseases owing to their ability to competitively antagonize β-adrenergic receptors (βARs). However, their use is often limited by adverse effects such as fatigue, hypotension, and reduced exercise capacity, due in part to nonselective inhibition of multiple βAR subtypes. These challenges are particularly problematic in treating catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease characterized by lethal tachyarrhythmias directly triggered by cardiac β 1 AR activation. To identify small-molecule allosteric modulators of the β 1 AR with enhanced subtype specificity and robust functional antagonism of β 1 AR-mediated signaling, we conducted a DNA-encoded small-molecule library screen and discovered Compound 11 (C11). C11 selectively potentiates the binding affinity of orthosteric agonists to the β 1 AR while potently inhibiting downstream signaling after β 1 AR activation. C11 prevents agonist-induced spontaneous contractile activity, Ca 2+ release events, and exercise-induced ventricular tachycardia in the CSQ2 –/– murine model of CPVT. Our studies demonstrate that C11 belongs to an emerging class of allosteric modulators termed positive allosteric modulator antagonists that positively modulate agonist binding but block downstream function. Its pharmacological properties and selective functional antagonism of β 1 AR-mediated signaling make C11 a promising therapeutic candidate for the treatment of CPVT and other forms of cardiac disease associated with excessive β 1 AR activation.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (HL056687)
- National Heart, Lung, and Blood Institute (HL16037)
- Edna and Fred L. Mandel, Jr. Foundation (N/A)
- John Taylor Babbit Foundation (N/A)
- Hartwell Foundation (N/A)
- Instituto Nacional de Cancerología (P30CA014236)
- Howard Hughes Medical Institute (N/A)
This publication has 49 references indexed in Scilit:
- Allosteric Modulation of the Cannabinoid CB1 ReceptorMolecular Pharmacology, 2005
- Receptor-specific Ubiquitination of β-Arrestin Directs Assembly and Targeting of Seven-transmembrane Receptor SignalosomesJournal of Biological Chemistry, 2005
- Seven-transmembrane receptorsNature Reviews Molecular Cell Biology, 2002
- Allosteric binding sites on cell-surface receptors: novel targets for drug discoveryNature Reviews Drug Discovery, 2002
- Molecular Determinants Underlying the Formation of Stable Intracellular G Protein-coupled Receptor-β-Arrestin Complexes after Receptor Endocytosis*Journal of Biological Chemistry, 2001
- Cardiovascular and Metabolic Alterations in Mice Lacking Both β1- and β2-Adrenergic ReceptorsJournal of Biological Chemistry, 1999
- Control of Myocardial Contractile Function by the Level of β-Adrenergic Receptor Kinase 1 in Gene-targeted MiceJournal of Biological Chemistry, 1998
- A novel mechanism of activity‐dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones.The Journal of Physiology, 1996
- Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects.Proceedings of the National Academy of Sciences, 1996
- Anti–β1-adrenergic receptor antibodies and heart failure: causation, not just correlation